Zinc Carnosine for Gastritis: Evidence-Based Recommendation
Zinc carnosine (polaprezinc) can be used as an adjunctive therapy for gastritis, particularly when associated with H. pylori infection or when standard treatments have not fully resolved symptoms, but it should not replace guideline-recommended H. pylori eradication therapy as first-line treatment.
Primary Treatment Framework
The established guidelines are clear: for H. pylori-associated gastritis, bismuth quadruple therapy or concomitant therapy remains the first-line treatment 1. Eradication of H. pylori cures gastritis in over 90% of patients and is strongly recommended for all infected patients 2. This is non-negotiable as the primary approach.
Role of Zinc Carnosine
When to Consider Zinc Carnosine:
1. As Adjunctive Therapy to H. pylori Eradication:
- Adding zinc carnosine to standard triple therapy improves H. pylori eradication rates (OR: 2.01 for intention-to-treat analysis) without increasing adverse events 3
- It enhances the effectiveness of antibiotic regimens through anti-inflammatory and antioxidant mechanisms 4, 5
2. For Persistent Dyspeptic Symptoms:
- When gastritis symptoms persist despite successful H. pylori eradication
- Zinc carnosine demonstrates direct mucosal cytoprotective effects and promotes repair of mucosal injury 6, 7
- Dosing: 39.5 mg (or equivalent polaprezinc dose) twice daily for at least 12 months showed clinical benefit 8
3. For Chronic Atrophic Gastritis:
- Recent case reports show histologic improvement in chronic atrophic gastritis with long-term zinc carnosine therapy 8
- This is particularly relevant as atrophic gastritis is a recognized precancerous condition 9, 10
- Improvements were noted in both dyspeptic symptoms and gastric function markers (pepsinogen I/II, gastrin-17)
Mechanism of Action:
Zinc carnosine works through:
- High affinity for inflamed/damaged tissue with localized zinc release 7
- Anti-inflammatory effects by reducing IL-8 production and neutrophil infiltration 4, 5
- Antioxidant properties that reduce oxidative stress in gastric mucosa 4
- Direct mucosal cytoprotective and membrane-stabilizing effects 7
Evidence Quality:
The evidence for zinc carnosine is primarily from:
- Moderate-quality RCTs showing efficacy comparable to rebamipide for gastric ulcers 11
- Meta-analysis demonstrating benefit as adjunct to H. pylori therapy 3
- Case reports suggesting histologic improvement in atrophic gastritis 8
- Animal and in vitro studies supporting anti-inflammatory mechanisms 4, 5
Clinical Algorithm:
Step 1: Confirm H. pylori status (stool antigen or urea breath test) 12
Step 2: If H. pylori positive → Initiate bismuth quadruple therapy or concomitant therapy 1
- Consider adding zinc carnosine 75-150 mg daily to improve eradication rates 3
Step 3: If H. pylori negative or symptoms persist post-eradication:
- Start zinc carnosine 75-150 mg daily (divided doses) for symptomatic relief 8, 6
- Continue for minimum 8-12 weeks; extend to 12+ months for atrophic gastritis 8
Step 4: For atrophic gastritis (confirmed histologically):
- Ensure H. pylori eradication first 9, 10
- Add zinc carnosine as long-term therapy (12+ months) 8
- Monitor with endoscopy and histology at 12-month intervals 10
Important Caveats:
- Zinc carnosine is NOT a substitute for H. pylori eradication therapy - the guidelines universally prioritize antibiotic-based eradication 1, 9
- For autoimmune gastritis, zinc carnosine may provide symptomatic benefit but does not address the underlying autoimmune process 8
- Safety profile is favorable with adverse events comparable to placebo 11, 3
- The evidence base, while promising, consists mainly of Asian studies; Western data are limited 11, 3
What Doesn't Work:
Avoid using zinc carnosine as monotherapy for H. pylori-positive gastritis - this delays appropriate antibiotic treatment and risks progression to atrophic changes and gastric cancer 1, 9.